A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

Phase 3 Completed NCT06034743

Summary

This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).

Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat

At Week 12 · mmHg

Change From Baseline in Seated Systolic Blood Pressure for 1 mg Baxdrostat

At Week 12 · mmHg

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes — University of Alabama at Birmingham
• Improving Hypertension Medication Adherence for Older Adults — University of Arizona
• A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Ar — Actelion
• LiveSMART Trial to Prevent Falls in Patients With Cirrhosis — University of Michigan
• SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode R — Medtronic Vascular
• Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test — Stanford University

All trials